ONCODESIGN AND GALDERMA SIGN PARTNERSHIP AGREEMENT.

 
FREE EXCERPT

ONCODESIGN has partnered with Galderma, a dermatological unit belonging to Nestle Skin Health.

The primary aim of this multi-year service agreement is to design and discover new skincare drug candidates, through close cooperation with Galderma's own research teams, leveraging Oncodesign's ability to validate the therapeutic potential of new molecular targets of interest to Galderma.

About ONCODESIGN

Founded over 20 years ago by Dr Philippe Genne, the Company's CEO and Chairman, Oncodesign is a biopharma company dedicated to the precision medicine. Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25%...

To continue reading

FREE SIGN UP